Cyclin B1 Antibody (Y106)

Product Discontinued

Cyclin B1 Antibody (Y106) Summary

• Immunogen: A synthetic peptide corresponding to residues in C-terminus of human cyclin B1 was used as immunogen.
• Marker: Mitosis Marker
• Specificity: The antibody does not cross-react with other cyclin family members.
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Gene: CCNB1
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 1:100
  • Immunocytochemistry/ Immunofluorescence 1:50
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Paraffin 1:100
  • Immunoprecipitation 1:100
  • Western Blot 1:10000-50000
• Application Notes: In Western blot this antibody detects a band at approximately 58 kDa.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: 49% PBS, 0.05% BSA and 50% Glycerol
• Preservative: 0.01% Sodium Azide
• Purity: Protein A purified

Notes

Produced using Abcam's RabMab® technology. RabMab® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

Alternate Names for Cyclin B1 Antibody (Y106)

• CCNB
• CCNB1
• Cyclin B1
• G2/mitotic-specific cyclin B1
• G2/mitotic-specific cyclin-B1

Background

Cyclin B1 regulates mitosis in conjunction with Cdc2 kinase to form the Cdc2-cyclin B1 complex also known as maturation promoting factor (MPF) (1-2). The activation of the complex begins when the regulatory subunit, cyclin B1, associates with the catalytic subunit of Cdc2. Cyclin B1 levels rise during S phase and G2, and peak at mitosis. The timing of mitosis can also be influenced by changes in cyclin B1

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Cyclin B1 Antibody (NB110-56900)(3)

Publications using NB110-56900

• Tsavachidou-Fenner D, Tannir N, Tamboli P et al. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann Oncol. 2010-08-01 [PMID: 20089566]
• Agarwal R, Gonzalez-Angulo AM, Myhre S et al. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 2009-06-01 [PMID: 19470724]
• Hennessy BT, Lu Y, Poradosu E et al. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 2007-12-01 [PMID: 18094426] (WB)

Bioinformatics

• Gene Symbol: CCNB1
• Entrez:
  • 891(Human)
  • 268697(Mouse)
  • 25203(Rat)
• Uniprot:
  • P14635(Human)